January 16, 2020 09:00 AM ESTUpdated 12:29 PM
Financing

Fra­zier clos­es 12th fund in 30 years, with $617M to bet on cell/gene ther­a­py, Big Phar­ma spin­offs and more

Amber Tong

The team at Fra­zier Health­care did a num­ber of deals that ex­em­pli­fied its wide-rang­ing strat­e­gy in 2019: Tachi Ya­ma­da worked with gene ther­a­py pi­o­neer Jim …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

A service from the Financial Times